Skip to content

International Psychometric Validation Study of the Intestinal Gas Questionnaire (IGQ)

International Psychometric Validation Study of the Intestinal Gas Questionnaire (IGQ)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03002584
Acronym
PRoVING
Enrollment
300
Registered
2016-12-26
Start date
2017-02-10
Completion date
2018-07-10
Last updated
2019-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General Population, IBS - Irritable Bowel Syndrome

Keywords

IBS, population

Brief summary

Objective: To confirm the psychometrics properties of the Intestinal Gas Questionnaire (IGQ) in subjects with Irritable Bowel Syndrome (IBS) diagnosis and General population both complaining of Gas-Related Symptoms (GRS). IGQ has been developed previously simultaneously in UK English, French and Spanish through qualitative research with subject interviews. The conceptual framework of the IGQ assesses both GRS and their impact on daily life. Similar concepts were identified for both subjects with IBS diagnosis and general population and complaining of gas-related symptoms. The IGQ consists of a 24-hour recall symptom diary assessing 7 gas-related symptoms (17 items) and a 7-day recall questionnaire which assesses the impact of those symptoms (26 items)

Detailed description

Observational (non-interventional) study with a cross-sectional part for a subset of adult subjects with a single IGQ completion and a longitudinal cross-over part for a subset of subjects with test-retest IGQ completion for validation of electronic version of IGQ. 300 eligible subjects (100 in each of the 3 countries: France, UK & Spain): * 180 with IBS diagnosis (60% of recruited subjects) * 120 from General population (40% of recruited subjects)

Interventions

Single completion: Participants will have to complete the IGQ, the generic health status EQ-5D questionnaire, the specific FDDQL questionnaire (Functional Digestive Disorders Quality of Life). Test-retest: during the second completion within a mean 7-day interval, participants will complete the IGQ and a single global Gastro-Intestinal Well-Being scale

Sponsors

EA 7334, Patient-Centered Outcomes Research
CollaboratorUNKNOWN
University of Manchester
CollaboratorOTHER
Hospital Vall d'Hebron
CollaboratorOTHER
Hôpital Louis Mourier
CollaboratorOTHER
University Paris 7 - Denis Diderot
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

All (subjects with IBS diagnosis and general population): * Complaining of gas-related symptoms (GRS) of a certain severity level: subjects with IBS diagnosis and general population need to report a score of 4 or greater on at least one symptom on the symptom screening tool * Cognitive and linguistic capability to complete several self-questionnaires * BMI \> 18.5 and \< 30.0 kg/m2 * Agreement of the subject to participate in the study Subjects with IBS diagnosis: * IBS diagnosis using Rome III diagnostic criteria for Functional Gastrointestinal Disorders (21) * IBS severity: IBS-SSS score of 75 to 300 General population: * Subjects not fulfilling IBS Rome III criteria * Regular stool frequency (i.e., between 3 and 21 bowel movements per week)

Exclusion criteria

All (subjects with IBS diagnosis and general population): * Recent (2 last weeks) change in diet or intake of potentially flatulogenic compounds (fiber, lactulose) * Organic gastrointestinal disease * Other functional gastrointestinal disorder as defined by Rome III criteria * Any severe and progressive disease (e.g. depression, cancer, uncontrolled diabetes, rheumatoid arthritis…) * Any severe psychiatric disorder (e.g. acute episode of schizophrenia or bipolar disorder…) * Pregnant women * Being under the direct hierarchy of the investigatorBelonging to the site's staff team General population: * Treatment for diarrhea or constipation including lactulose

Design outcomes

Primary

MeasureTime frameDescription
Psychometric validation of the IGQcross sectional for 70% of participants and test-retest within an interval of 7 days for 30% of participantsStastistical analysis to confirm the psychometric validation of the IGQ questionnaire

Secondary

MeasureTime frameDescription
Electronic version of the IGQDuring test-retest within an interval of 7 daysComparison of scores between paper and electronic version of IGQ

Countries

France, Spain, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026